NPS Pharmaceuticals

Latest Headlines

Latest Headlines

NPS, Iroko show how companies can grow sales, not staff

Big Pharma has been whacking a lot of jobs in the last couple of years, part of its periodic boom-and-bust cycle of hiring when times are good and firing when they are not. But some small drug companies have been trying a different model: Just don't add employees in the first place.

With NIH support, Eli Lilly follows NPS Pharma into hunt for rare-disease therapy

Eli Lilly has found a new path into the hot rare-disease field. An NIH program has backed the Indianapolis-based drug giant's preclinical-stage research of a potential treatment for a hormone deficiency often caused by a genetic defect. 

NPS begins to rack up sales of pricey SBS drug

NPS Pharmaceuticals ($NPSP) racked up the first quarterly score on its $295,000-a-year treatment for short bowel syndrome, claiming early traction for Gattex. To be sure, the numbers are small: 42 patients and 160 prescriptions in Q1.

NPS Pharma goes global with $80M deal to buy back Takeda's Gattex rights

NPS Pharmaceuticals has locked up the global rights to Gattex. The biotech bought back the ex-U.S. rights to its newly approved orphan drug (teduglutide) alongside another drug program close to a U.S. filing for rare cases of hypoparathyroidism, handing over $50 million in stock--a 7% equity stake in the company--with another $30 million on the table if the company hits a key sales milestone.

Last-minute drive at FDA added 6 new drug approvals

Our readers who regularly check our website know that we kept up with the news online. But for everyone else, here's a roundup of the regulatory actions you may have missed.

NPS Pharma bags FDA approval for bowel drug

The FDA has stamped an approval on NPS Pharmaceuticals' Gattex for treating patients with short bowel syndrome. The approval sets the stage for the U.S. launch of the company's lead drug and adds to U.S. regulators' impressive tally of more than 30 new drug nods in 2012.

FDA advisers back NPS Pharma's orphan bowel drug

If all goes as planned for NPS, the FDA will heed the advice of its panel of non-agency experts and stamp an approval on the drug before the end of the year.

NPS Pharma shares jump on upbeat FDA review of Gattex

NPS Pharmaceuticals got a big boost this morning when the FDA issued an upbeat preview of its short bowel syndrome drug Gattex, endorsing the developer's efficacy claims and key aspects of the risk evaluation and mitigation strategy it proposed to manage a potential cancer risk, among other safety issues.

NPS wraps another positive PhIII study as parathyroid drug impresses

A week after giving investors a Halloween scare with the news of two cancer deaths in a critical trial of Gattex, NPS Pharmaceuticals ($NPSP) followed up with positive top-line results from a pivotal

NPS Pharma shares sink after cancers reported in patients on bowel drug

NPS Pharmaceuticals gave investors a reason to run yesterday, but at least one analyst says today that the reaction was too much. The Bedminster, NJ-based developer said that three patients at sites